Sarah Harris, PhD

Bristol Myers Squibb

Poster(s):

• E0354 - Association Between Absolute Lymphocyte Count and Ozanimod Efficacy/Safety in Patients With Moderate/Severe Ulcerative Colitis: Results From the Phase 3 True North Study
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET

• E0355 - Impact of Ozanimod on Fecal Calprotectin Levels and the Association With Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 True North Study
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET